The Biostatistics Shared Resource of the Mayo Clinic Cancer Center (MCCC) has provided expert statistical collaboration with MCCC investigators for over 30 years. The purpose of the resource is to provide statistical and biomathematical collaboration for the development and conduct of peer-reviewed cancer research generated by investigators in the MCCC. This research ranges from the bench to the bedside to the population, and encompasses basic science, clinical trials, epidemiologic research, and other translational and educational research. The primary usage of the funds provided to the resource by the CCSG is to support statistical and mathematical collaboration on pilot projects, for assistance to investigators in developing approved research projects not otherwise funded but leading towards external funding, and to support unanticipated needs for statistical collaboration on MCCC approved projects. Over the 30 year history of the Biostatistics Shared Resource, the group has undergone a natural and deliberate evolution and expansion, spurred by the expanding research activities of the MCCC. The Biostatistics Shared Resource has multiple focus areas (teams) tied together into a well-organized, efficient core. These are: (I) a Clinical Trials team responsible for cancer clinical trials, associated translational research, interventional psychosocial research, and imaging, together with patient and public education research projects, (II) a Population Science team responsible for providing statistical collaboration and data management support for cancer observational studies, including genetic and molecular epidemiology, (III) a Quality of Life team responsible for providing general and specific advice, measurement tools, and analysis for MCCC investigators who are investigating the impact of clinical and psychosocial interventions on cancer patients, families, caregivers, and others, and (IV) a Biomathematics team that provides collaborative expertise in the mathematical aspects of imaging, data processing and analysis, mathematical modeling (e.g. of tumor growth), and general mathematical or algorithmic issues. These groups work efficiently and effectively together to provide statistical and biomathematical collaboration to Mayo Clinic Cancer Center investigators across all three MCCC campuses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-33
Application #
7414490
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
33
Fiscal Year
2007
Total Cost
$804,754
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320

Showing the most recent 10 out of 1129 publications